An official website of the United States government.

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Research Publications (Food Safety)

This page tracks research articles published in national and international peer-reviewed journals. Recent articles are available ahead of print and searchable by Journal, Article Title, and Category. Research publications are tracked across six categories: Bacterial Pathogens, Chemical Contaminants, Natural Toxins, Parasites, Produce Safety, and Viruses. Articles produced by USDA Grant Funding Agencies (requires login) and FDA Grant Funding Agencies (requires login) are also tracked in Scopus.

Displaying 1 - 21 of 21

  1. Bacterial isolates, antibiogram and outcomes of blood culture proven sepsis in neonates at a tertiary institution in South East Nigeria: a cross-sectional study

    • Therapeutic Advances in Infectious Disease
    • Background:Neonatal sepsis (NNS) in developing countries continues to be a diagnostic and management challenge due to the delays in identifying the aetiologic pathogens and antibiograms.Aim:To determine the predominant bacterial isolates, antibiotic susceptibility pattern and outcomes of blood culture proven sepsis in neonates.Methodology:A hospital-based cross-sectional study of 120 neonates admitted into the Special Care Baby Unit (SCBU) of Nnamdi Azikiwe University Teaching Hospital Nnewi

      • Bacterial pathogens
      • Staphylococcus aureus
  2. Trends and characteristics of primary pyogenic spine infections among people who do and do not inject drugs: Northeast New York State, 2007 to 2018

    • Therapeutic Advances in Infectious Disease
    • Background:Pyogenic spine infections (PSIs) are challenging to diagnose and treat. People who inject drugs (PWID) are at increased risk and contribute to rising PSI incidence.Objective:To analyze trends and characterize PSI in persons who do and do not inject drugs in northeast New York State (NYS), a predominantly rural region.Methods:A retrospective study of PSI patients at a regional tertiary care hospital from 2007 to 2018 was conducted.

      • Bacterial pathogens
      • Staphylococcus aureus
  3. The use of technology-based adherence monitoring in the treatment of hepatitis C virus

    • Therapeutic Advances in Infectious Disease
    • Direct-acting antivirals (DAAs) achieve high hepatitis C virus (HCV) cure rates and are forgiving to missed doses, but adherence–efficacy relationships have not been well defined. Traditional adherence measures (e.g. pill counts, self-report and pharmacy refills) over-estimate medication adherence. Newer technology-based tools have been used to provide more objective adherence data.

      • Viruses
      • Hepatitis
  4. Intravenous Drug Use: a Significant Risk Factor for Serratia Bacteremia

    • Therapeutic Advances in Infectious Disease
    • Background:Serratia is an opportunistic pathogen known to cause an array of infectious presentations. Aside from case reports, intravenous (IV) drug use has not been adequately quantified as a major risk factor for Serratia infection.Methods:A retrospective cohort study of 103 adult patients admitted to four community hospitals in Ohio from January 2014 to December 2018 with a positive blood culture for Serratia species.

      • Viruses
      • Hepatitis
  5. Disease burden due to Group B Streptococcus in the Indian population and the need for a vaccine – a narrative review

    • Therapeutic Advances in Infectious Disease
    • Streptococcus agalactiae, a Gram-positive bacterium, causes invasive infection known as Group B streptococcal disease (GBS). It is a leading cause of neonatal death and complications prior to delivery. The burden of GBS is unknown in India despite the high incidence of preterm and stillbirths.

  6. A systematic review of historical and current trends in Chagas disease

    • Therapeutic Advances in Infectious Disease
    • Introduction:Chagas disease (CD) is caused by Trypanosoma cruzi. When acquired, the disease develops in stages. For diagnosis, laboratory confirmation is required, and an extensive assessment of the patient’s health should be performed. Treatment consists of the administration of trypanocidal drugs, which may cause severe adverse effects.

  7. The impact of COVID-19 on tuberculosis: challenges and opportunities

    • Therapeutic Advances in Infectious Disease
    • The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a seafood market in Wuhan, China, has ushered in a new era. It transformed into a pandemic, seized global attention, and was the biggest highlight of the year 2020. The SARS-CoV-2 outbreak has jeopardized health systems and greatly affected socioeconomic parameters. With global focus on fighting this unpredictable fight with this new virus, the biggest chronic infectious killer, mycobacterium tuberculosis (M.

      • Bacterial pathogens
  8. Oral candidiasis in HIV-uninfected pediatric population in areas with limited fungal diagnosis: A case study from a tertiary hospital, Tanzania

    • Therapeutic Advances in Infectious Disease
    • Background:Oral candidiasis (OC) is an indirect indicator of cell-mediated immunodeficiency with a high predictive value of disseminated candidiasis. Here, we report the prevalence and factors associated with laboratory-confirmed OC in human immunodeficiency virus (HIV)-uninfected children with clinical OC attending the outpatient clinic or admitted in pediatric wards of the Bugando Medical Center (BMC).Methods:A cross-sectional study was conducted between January and June 2017.

  9. Bacterial co-infections and antibiotic prescribing practice in adults with COVID-19: experience from a single hospital cluster

    • Therapeutic Advances in Infectious Disease
    • Background: Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected millions of individuals since December 2019, resulting in significant morbidity and mortality globally. During the 1918 Influenza Pandemic, it was observed that influenza was associated with bacterial co-infections. However, empirical or prophylactic antibiotic use during viral pandemics should be balanced against the associated adverse drug events.

      • Staphylococcus aureus
      • Bacterial pathogens
  10. Convalescent plasma appears efficacious and safe in COVID-19

    • Therapeutic Advances in Infectious Disease
    • A cluster of pneumonia cases of unknown etiology associated with pyrexia and acute respiratory distress was identified in Southern China. Links between the previous severe acute respiratory syndrome (SARS) cases and the region’s seafood market were noted with the possibility of a new zoonosis and SARS-CoV-2 was identified as the responsible agent.

      • Viruses
  11. Evaluating appropriateness and diagnostic stewardship opportunities of multiplex polymerase chain reaction gastrointestinal testing within a hospital system

    • Therapeutic Advances in Infectious Disease
    • Objective:This single-center, retrospective, observational cohort study evaluates the appropriateness of the BioFire® FilmArray® Gastrointestinal (GI) multiplex PCR panel testing at a community-teaching hospital.Methods:All adult, hospitalized patients at Prisma Health Richland Hospital with a documented GI multiplex PCR panel from 1 April 2015 through 28 February 2018 were included in the analysis.

      • Norovirus
      • Viruses
      • Bacterial pathogens
  12. Plazomicin: a new aminoglycoside in the fight against antimicrobial resistance

    • Therapeutic Advances in Infectious Disease
    • Objective:To review the mechanism of action, mechanisms of resistance, in vitro activity, pharmacokinetics, pharmacodynamics, and clinical data for a novel aminoglycoside.Data sources:A PubMed search was performed from January 2006 to August 2019 using the following search terms: plazomicin and ACHN-490. Another search was conducted on clinicaltrials.gov for published clinical data.

      • Bacterial pathogens
  13. Keeping alive enterprises while embracing unprecedented COVID-19 restrictions

    • Therapeutic Advances in Infectious Disease
      • COVID-19
  14. Why such excess of mortality for COVID-19 in Spain?

    • Therapeutic Advances in Infectious Disease
      • COVID-19
  15. Preventing SARS-CoV-2 infection by blocking a tissue serine protease

    • Therapeutic Advances in Infectious Disease
    • Currently, there are no proven pharmacologic interventions to reduce the clinical impact and prevent complications of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, the cause of the ongoing Coronavirus Disease of 2019 (COVID-19) pandemic. Selecting specific pharmacological targets for the treatment of viral pathogens has traditionally relied in blockage of specific steps in their replicative lifecycle in human cells.

      • COVID-19
  16. Chloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a narrative review

    • Therapeutic Advances in Infectious Disease
    • The predicament arising from the coronavirus disease 2019 (COVID-19) pandemic has become one of the most significant modern public health challenges. Despite uncertainties in the viral determinants and pathogenesis, it is crucial to accurately inspect all available evidence to construct accurate clinical guidelines for optimised patient care. This study aims to discuss the available evidence for the use of chloroquine (CQ) and hydroxychloroquine (HCQ) against COVID-19.

      • COVID-19
  17. Efficacy and safety of ceftaroline: systematic review and meta-analysis

    • Therapeutic Advances in Infectious Disease
    • Background:Resistance to antibiotics is steadily increasing.

      • Staphylococcus aureus
      • Bacterial pathogens
  18. Hepatitis E: an underestimated emerging threat

    • Therapeutic Advances in Infectious Disease
    • Hepatitis E virus (HEV) is the most common cause of viral hepatitis in the world. It is estimated that millions of people are infected every year, resulting in tens of thousands of deaths. However, these estimates do not include industrialized regions and are based on studies which employ assays now known to have inferior sensitivity. As such, this is likely to represent a massive underestimate of the true global burden of disease.

      • Viruses
      • Hepatitis
  19. Screening for retroviruses and hepatitis viruses using dried blood spots reveals a high prevalence of occult hepatitis B in Ghana

    • Therapeutic Advances in Infectious Disease
    • Background:Recent advances in antiviral therapy show potential for a cure and/or control of most human infections caused by hepatitis viruses and retroviruses. However, medical success is largely dependent on the identification of the large number of people unaware of these infections, especially in developing countries.

      • Viruses
      • Hepatitis
  20. Daptomycin dosing in obese patients: analysis of the use of adjusted body weight versus actual body weight

    • Therapeutic Advances in Infectious Disease
    • Background:Food and Drug Administration–approved daptomycin dosing uses actual body weight, despite limited dosing information for obese patients. Studies report alterations in daptomycin pharmacokinetics and creatine phosphokinase elevations associated with higher weight-based doses required for obese patients.

  21. Effectiveness of oral antibiotics for definitive therapy of non-Staphylococcal Gram-positive bacterial bloodstream infections

    • Therapeutic Advances in Infectious Disease
    • Background:Data on the effectiveness of definitive oral (PO) antibiotics for BSIs in preparation for discharge from hospital are lacking, particularly for Gram-positive bacterial BSIs (GP-BSI). The objective of this study was to determine rates of treatment failure based on bioavailability of PO antimicrobial agents used for GP-BSI.Methods:This was a single-center, retrospective cohort study of adult inpatients admitted to an academic medical center over a three-year period.